Yeni ve Gelecek Vaat Eden Teknolojiler
Özet
Bu akademik metin, genitoüriner kanserlerin, özellikle de prostat kanserinin tedavisinde geleneksel radikal cerrahi uygulamaları ve radyoterapinin yol açtığı erektil disfonksiyon ile üriner inkontinans gibi yaşam kalitesini ciddi derecede düşüren yan etkileri en aza indirmeyi amaçlayan yeni ve gelecek vaat eden fokal ablasyon teknolojilerini detaylı bir şekilde incelemektedir. Teknolojik ilerlemeler ve modern bilgisayar yazılımlarının gelişmiş görüntüleme yöntemleriyle entegrasyonu sayesinde hayat bulan bu minimal invaziv yöntemler, tümörün geliştiği organa minimal zarar vererek kanserli dokuyu ablate etmeyi hedefler. Çalışmada öne çıkan üç temel teknoloji sırasıyla Vasküler Hedefli Fotodinamik Terapi (VTP), İrreversibl Elektroporasyon (IRE) ve Transüretral Ultrason Ablasyonudur (TULSA). VTP, ışığa duyarlı padeliporfin gibi ajanların belirli bir lazer ışığıyla aktive edilerek tümörün yeni oluşan damar sisteminde tıkanmaya yol açması prensibiyle çalışır. IRE teknolojisi, ultra kısa süreli pulsatil elektrik akımı impulsları vasıtasıyla hücre membranında nano boyutta gözenekler açıp apoptozisi tetiklerken kritik damar ve sinir yapılarını tamamen korur. TULSA ise MRI rehberliğinde transüretral ultrason dalgaları aracılığıyla yüksek sıcaklıklara ulaşarak içten dışa doğru hassas bir termal ablasyon gerçekleştirir. Erken dönem sonuçları oldukça güvenilir ve umut verici olan bu yenilikçi fokal tedavilerin birinci basamak tedavi seçenekleri arasına girebilmesi adına uzun dönemli randomize kontrollü çalışmalara ihtiyaç vardır.
This academic text examines new and promising focal ablation technologies aimed at minimizing the significant side effects, such as erectile dysfunction and urinary incontinence, caused by traditional radical surgery and radiotherapy in the treatment of genitourinary cancers, particularly prostate cancer. Driven by advancements in technology and the integration of sophisticated computer software with modern imaging techniques, these minimally invasive methods target the ablation of tumor tissues while causing minimal damage to the host organ. The study highlights three primary modalities: Vascular-Targeted Photodynamic Therapy (VTP), Irreversible Electroporation (IRE), and Transurethral Ultrasound Ablation (TULSA). VTP functions by activating light-sensitive agents like padeliporfin with laser light to induce permanent vascular occlusion in the tumor's newly formed vessels. IRE relies on ultra-short, pulsatile electrical currents to create nanoscale pores in cell membranes and trigger apoptosis, safely preserving adjacent critical nerves and large blood vessels. Lastly, TULSA utilizes MRI-guided transurethral ultrasound waves to generate high temperatures for precise inside-out thermal tissue ablation. Although early clinical outcomes demonstrate that these short-term focal therapies are highly reliable and promising for organ-confined diseases, comprehensive long-term randomized controlled trials and standardization are still required before they can become primary first-line treatment alternatives.
Referanslar
Dos Santos A.F., De Almeida DR Q., Terra L.F., Baptista M.S., Labriola L. Photodynamic therapy in cancer treatment—An update review. J. Cancer Metastasis Treat. 2019;5:25.
Von Tappeiner H. Therapeutische Versuche mit fluoreszierenden Stoffen. Munch. Med. Wochenschr. 1903;1:2042–2044
Nogueira L, Tracey AT, Alvim R, Reisz P, Scherz A, Coleman JA, Kim K.Molecules Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies. Molecules. 2020 Nov 19;25(22):5417.
Davidson S.R.H., Weersink R., Haider M.A., Gertner M.R., Bogaards A., Giewercer D., Scherz A., Sherar M.D., Elhilali M., Chin J.L., et al. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys. Med. Biol. 2009;54:2293–2313.
Bugaj A.M. Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer—Clinician’s insight. World J. Methodol. 2016;6:65–76.
Nogueira L., Wang L., Fine S.W., Pinochet R., Kurta J.M., Katz D., Savage C.J., Cronin A.M., Hricak H., Scardino P.T., et al. Focal treatment or observation of prostate cancer: Pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology. 2010;75:472–477.
Eymerit-Morin C., Zidane M., Lebdai S., Triau S., Azzouzi A.R., Rousselet M.-C. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Archiv. 2013;463:547–552.
Madar-Balakirski N., Tempel-Brami C., Kalchenko V., Brenner O., Varon D., Scherz A., Salomon Y. Permanent occlusion of feeding arteries and draining veins in solid Mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS ONE. 2010;5:e10282.
Kimm S.Y., Tarin T.V., Monette S., Srimathveeravalli G., Gerber D., Durack J.C., Solomon S.B., Scardino P.T., Scherz A., Coleman J. Nonthermal Ablation by Using Intravascular Oxygen Radical Generation with WST11: Dynamic Tissue Effects and Implications for Focal Therapy. Radiology. 2016;281:109–118.
Murray K.S., Winter A.G., Corradi R.B., LaRosa S., Jebiwott S., Somma A., Takaki H., Srimathveeravalli G., Lepherd M., Monette S., et al. Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine. J. Urol. 2016;196:236–243.
Preise D., Oren R., Glinert I., Kalchenko V., Jung S., Scherz A., Salomon Y. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol. Immunother. 2008;58:71–84.
Kraus D., Palasuberniam P., Chen B. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy. Mol. Cancer Ther. 2017;16:2422–2431.
Muller B.G., Fütterer J.J., Gupta R.T., Katz A., Kirkham A., Kurhanewicz J., Moul J.W., Pinto P.A., Rastinehad A.R., Robertson C., et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: Recommendations from a consensus panel. BJU Int. 2014;113:218–227.
Azzouzi A-R, Vincendeau S, Barret E, Cicco A, Kleinclauss F,van der Poel HG, et al.Padeliporfin vascular-targeted photo-dynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label,phase 3, randomised controlled trial. Lancet Oncol . 2016; 18:181–91.
Moore CM, Azzouzi AR, Barret E, Villers A, Muir GH, Barber NJ, Bott S, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11- vascular-targeted photodynamic (VTP) therapy..BJU Int. 2015; 116(6):888-96.
Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, PCM301 Study Group Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.Lancet Oncol 18(2):181.
Tracey, A.; Noguiera, L.; Alvim, R.; Wong, N.; Demac, Q.; McGill, M.; Sjoberg, D.; Estes, C.; ODea, C.;Benfante, N.; et al. LBA02-04 Interim Results: A Phase 2B Trial of Padeliporfin (WST11) Vascular-TargetedPhotodynamic Therapy as Partial-Gland Ablation for Men with Intermediate-Risk Prostate Cancer. J. Urol. 2020, 203 (Suppl. S4), e1116.
Nollet JA. Recherches sur les causes particulieres des phenomenes electriques 1754 Paris: Chez H.L Guerin & L.F. Delatour.
Ivorra A, Rubinsky B. History review of irreversible electroporation in biomedical engineering. Springer, Berlin 2010; 1-21
Fuller GW. Report on the investigations into the purification of the Ohio river water at Louisville Kentucky; 1898: Van Nostrand Company, New York.
Sale AJH, Hamilton WA. Effects of high electric fields on microorganisms. 1. Killing of bacteria and yeasts. Biochim Biophys Acta 1967; 148: 781.
Hamilton WA, Sale AJH. Effects of high electric fields on microorganisms. 2. Mechanism of action of the lethal effect. Biochim Biophys Acta 1967; 148: 789.
Pinero J, Lopez-Baena M Ortiz T et al. Apoptosis and necrotic cell death are both induced by electroporation in HL60 human promyeloid leukaemia cells. Apoptosis 1997; 2: 330.
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005 Feb;33(2):223-31.
Charpentier KP, Wolf F, Noble L et al. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011; 13: 168.
Deodhar A, Monette S, Single GW et al. Renal tissue ablation with irreversible electroporation: preliminary results in a porcine model. Urology 2011; 77. 754
Lee YJ, Lu DS, Osuagwu F, Lassman C. Irreversible electroporation in porcine liver: short- and long-term effect on the hepatic veins and adjacent tissue by CT with pathological correlation. Invest Radiol. 2012 Nov;47(11):671-5.
Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007; 6: 295.
Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2021 Apr;39(4):1107-1114.
Collettini F, Enders J, Stephan C, Fischer T, Baur ADJ, Penzkofer T, Busch J, Hamm B, Gebauer B. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. Radiology. 2019 Jul;292(1):250-257.
Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int. 2017 Nov;120 Suppl 3:51-58. doi: 10.1111/bju.13991. Epub 2017 Sep 19. PMID: 28834167.
Wah TM, Lenton J, Smith J, Bassett P, Jagdev S, Ralph C, Vasudev N, Bhattarai S, Kimuli M, Cartledge J. Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. Eur Radiol. 2021.
Liu B, Clark J, Domes T, Wall C, Jana K. Percutaneous irreversible electroporation for the treatment of small renal masses: The first Canadian case series. Can Urol Assoc J. 2019 Jan 21;13(9):E263-E267.
Dai JC, Morgan TN, Steinberg RL, Johnson BA, Garbens A, Cadeddu JA. Irreversible Electroporation for the Treatment of Small Renal Masses: 5-Year Outcomes. J Endourol. 2021 Aug 18. doi: 10.1089/end.2021.0115. Epub ahead of print. PMID: 33926224.
Nair SM, Hatiboglu G, Relle J, Hetou K, Hafron J, Harle C, Kassam Z, Staruch R, Burtnyk M, Bonekamp D, Schlemmer HP, Roethke MC, Mueller-Wolf M, Pahernik S, Chin JL. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. BJU Int. 2021 May;127(5):544-552.
Lumiani A, Samun D, Sroka R, Muschter R. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urol Oncol. 2021 Jun 15:S1078-1439(21)00173-3.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar;205(3):769-779.
